Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$8.42
-$0.70(-11.71%)
At close: 4:00 PM EST
$8.42
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $11.40
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.59M
Market Cap
$747.73M
Enterprise Value$469.68M
Total Cash (Recent Filing)$150.51M
Total Debt (Recent Filing)$41.87M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Feb 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding88,804,350
10 Day Avg. Volume1,967,120
30 Day Avg. Volume1,591,738
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)4.05
P/FCF Ratio-7.33
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue6.80
Enterprise Value/Gross Profit25.49
Enterprise Value/Ebitda-7.38
Forecast
1Y Price Target
$11.00Price Target Upside30.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$70.35M
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe MRD market is estimated to be over $20B, offering significant opportunity for PSNL despite being a later entrant into the market.
Medicare ReimbursementNeXT Personal received Medicare reimbursement for post-treatment monitoring for cancer recurrence in patients with stage II and III breast cancer.
Revenue GrowthPersonalis reported 3Q25 revenues of $14.5M, which beat the consensus estimate of $13.3M considerably.
Bears Say
Approval TimingThe company has now pushed their expected MRD MolDX approval timings twice in '25, with current guide calling for 2 approvals before YE, but does not include any revenue impact.
Revenue GuidanceManagement lowered their full year 2025 total revenue guidance range to $68M - $73M from prior $70M - $80M.
Stock Sell-OffThe stock sold off (~15%, on thin volumes) largely due to the reduced '25 guide, where 4Q revenues were guided (17%) below consensus.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $11.40 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $747.73M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Feb 19, 2026 which is in 56 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Nov 04, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.027.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.29.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,804,350 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -12.257%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (30.64% Upside)
$11.00 (30.64% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $266.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.51%
12-Months-Change
Fundamentals
Return on Equity
-43.69%
Trailing 12-Months
Asset Growth
1.23%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical adoption and strategic partnerships, but also revealed significant revenue and margin challenges. While the company is confident in its clinical and reimbursement advancements, financial performance faced headwinds due to biopharma volatility and revenue declines.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$11.00
▲(30.64% Upside)
Technical Analysis
Ownership Overview
0.68% Insiders
8.96% Mutual Funds
50.31% Other Institutional Investors
24.21% Public Companies and
Individual Investors